This is accomplished by blocking/minimizing the effects of estrogen in the body. To be more specific Clomid is chemically a synthetic estrogen with both agonist/antagonist properties, and is very similar in structure and action to Nolvadex. In certain target tissues it can block the ability of estrogen to bind with its corresponding receptor. Its clinical use is therefore to oppose the negative feedback of estrogens on the hypothalamic-pituitary-ovarian axis, which enhances the release of LH and FSH. This of course can help to induce ovulation.
Aug 2, 2011
Novogen Sells Consumer Health Business For $10m; Bioniche, Plasvacc Deal Falls Through; Bluechiip Gearing-Up For Commercialization; Anteo Appoints Mark Bouris Chairman; Federal Grant Underpins Vaxxas $15m For No Needle Patch; Cellmid Completes Technology Transfer, GMP Production; Up To 30% Of Votes Oppose Viralytics 29m Director Options; Leaf Appoints Ken Richards CEO, Dr Jay Hetzel Director; Orbis Takes Profit On More Acrux Shares; Australian Ethical Takes 13% Of Avita; Bone Appoints Founder Dr Roger New Chairman